Symptoms of peripheral arterial disease: ramipril
KEYWORDS: walking, ramipril, disease, people, ahimastos, peripheral, arterial, arterial disease, peripheral arterial, reported, intermittent, intermittent claudication, claudication, evidence, summary

Journal of the American Medical Association (JAMA), which advises that the study has been retracted after the lead author admitted to fabricating the results of this and a related study. This author was also the lead author for another study included in this evidence summary (Ahimastos et al. 2006) and it is unclear whether the integrity of that study is also affected. However, because of the paucity of evidence, the decision has been taken to present the results, with the proviso that the data may not be robust. Regulatory status: Ramipril is licensed for reducing cardiovascular risk in people with peripheral arterial disease, but its use to treat symptoms of peripheral arterial disease is off-label. Effectiveness Safety Compared with placebo over • According to the summary of product 24 weeks, ramipril 10 mg daily characteristics for Tritace, common adverse statistically significantly improved: effects of ramipril (seen in between 1 in 10 and 1 in 100 people) include headache, dizziness, • mean maximum walking time cough, sinusitis, dyspnoea, gastrointestinal and mean pain-free walking disturbances, rash, muscle spasms, myalgia, time (Ahimastos et al. 2006, hyperkalaemia, hypotension, syncope, chest n=40; both p<0.001; clinical pain and fatigue. importance unclear) • No adverse effects were
